LOS ANGELES, April 15 (Xinhua) -- The U.S. Food and Drug Administration (FDA) has warned consumers not to use counterfeit Ozempic (semaglutide) found in the U.S. drug supply chain.
The FDA said on Monday it was notified by Novo Nordisk, the drugmaker of Ozempic, that several hundred units of counterfeit Ozempic injection 1mg were in the U.S. drug supply chain. The FDA seized the identified counterfeit products on April 9.
The agency advises patients, wholesalers, retail pharmacies and health care professionals to check the Ozempic products they have received and not use, distribute or sell products labeled with lot number PAR0362 and serial number starting with the first eight digits 51746517.
The FDA said it is aware of six adverse event reports associated with this lot, but none of them appear to be associated with the counterfeit product.
An FDA investigation is underway.
